Impaired Body Weight and Tail Length Gain and Altered Bone Quality after Treatment with the Aromatase Inhibitor Exemestane in Male Rats

Author(s):
Gool, S.A. van; Wit, J.M.; Schutter, T. de; Clerck, N. de; Postnov, A.A.; Hovinga, S.K.; Doorn, J. van; Veiga, S.J.; Garcia-Segura, L.M.; Karperien, M.
Published
2010
Publication type
Article / Letter to editor

Abstract

Background: Estrogen deficiency induced by aromatase inhibitors may be a novel treatment modality for growth enhancement in short children, but may have adverse effects on bone, brain and reproduction. Aim: To assess growth effects and potential adverse effects of aromatase inhibition in male rats. Methods: 26-day-old prepubertal rats received intramuscular injections with placebo or the aromatase inhibitor exemestane at a dose of 10, 30 or 100 mg/kg/week [E10, E30, E100(6)] for 6 weeks, completely covering the sexual maturation phase, or with 3 weeks E100 followed by 3 weeks placebo [E100(3)]. Growth parameters and histology of the testis, seminal vesicle and brain were analyzed. Bone architecture was studied with X-ray microtomography. Results: Exemestane dose-dependently decreased body weight and tail length gain, as well as liver and seminal vesicle weights, but did not affect nose-anus length gain,

Estrogen Aromatase Aromatase inhibition Growth Osteopenia Growth plate maturation Sexual dimorphism Rat model estrogen-receptor specificity mineral density mice lacking reproductive phenotypes postmenopausal women brain aromatase p450 aromatase breast-cancer adult height final height
Date issued
2010-12-31
Language
English
Is part of
Hormone Research in Paediatrics (2010), Vol. 73, no. 5, p. 376-385
hdl
1887/110671